処理中

しばらくお待ちください...

Join our LinkedIn PATENTSCOPE users Community Group
設定

設定

出願の表示

官庁 all 言語 ja 語幹処理 true 同じパテント ファミリーに属する文献は 1 つにまとめて表示する false 非特許文献 (NPL) を含める false
RSS フィードを生成するには WIPO ユーザ アカウントが必要です

検索式の保存

プライベートに設定された検索式は、ユーザがログインしたときのみ表示可能であり、RSS フィードの購読はできません

検索式のツリー表示

条件の絞込み

官庁
全て
検索する言語を選択してください
語幹処理では、検索用語の語形変化を除いて、語幹のみを対象に解釈します。
例えば、「fishing」、「fished」、「fish」、「fisher」などの単語は、語形変化が除かれ、語幹の「fish」として解釈されます。
したがって、「fisher」という単語の検索結果では、語幹「fish」の語形が変化したさまざまな単語の検索結果も反映されます。
同じパテント ファミリーに属する文献は 1 つにまとめて表示
非特許文献 (NPL) を含める

検索式全体

IC:A61M AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

この画面で利用可能なショートカット キー

一般
検索入力欄に移動
CTRL + SHIFT +
結果一覧に移動
CTRL + SHIFT +
文献詳細に移動
CTRL + SHIFT +
次のページに進む
CTRL +
前のページに戻る
CTRL +
結果一覧での操作 ([結果一覧に移動] 後の操作)
次の文献/図に移動
/
前の文献/図に移動
/
上へスクロール
Page Up
下へスクロール
Page Down
一番上までスクロール
CTRL + Home
一番下までスクロール
CTRL + End
文献詳細での操作 ([文献詳細に移動] 後の操作)
次のタブに移動
前のタブに移動

結果分析

1.WO/2021/181261LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS
WO 16.09.2021
国際特許分類 (IPC) A61K 38/40
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
38ペプチドを含有する医療製剤
1621以上のアミノ酸をもつペプチド;ガストリン;ソマトスタチン;メラノトロピン;その誘導体
17動物由来;ヒト由来
40トランスフェリン,例.ラクトフェリン,オボトランスフェリン
出願番号 PCT/IB2021/051941 出願人 SOFAR S.P.A. 発明者 BIFFI, Andrea
The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.
2.20210330663PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, PREVENTING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
US 28.10.2021
国際特許分類 (IPC) A61K 31/4706
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
47キノリン;イソキノリン
47064-アミノキノリン;8-アミノキノリン,例.クロロキン,プリマキン
出願番号 17371009 出願人 CENTRE FOR DIGESTIVE DISEASES 発明者 Thomas Julius BORODY

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™), wherein optionally each or both of the opaganib and the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (e.g., PLAQUENIL™) are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, liquid or powder.

3.2021261049Products of manufacture and methods for treating, ameliorating or preventing microbial infections
AU 28.10.2021
国際特許分類 (IPC) A61K 31/4706
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
47キノリン;イソキノリン
47064-アミノキノリン;8-アミノキノリン,例.クロロキン,プリマキン
出願番号 2021261049 出願人 Topelia Aust Limited 発明者 BORODY, Thomas Julius
Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma "puffer-like" device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Said drug combinations include various combinations of antivirals, antiparasitics, antibacterials, and adjunct therapeutics, including at least one of Hydroxychloroquine, Chloroquine, Oseltamivir, Lopinavir, Ritonavir, Ribavirin, Favipiravir, Remdesivir, Azithromycin, Ivermectin, Doxycycline, and Opaganib or combinations thereof. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza vims, respiratory syncytial vims, picornavims, parainfluenza vims, adenovims, rhinovims, human metapneumovims, hantavimses, enterovims, a coronavims infection, or a COVID-19 or a 2019-nCoV (SARS-CoV-2) infection, or an infection caused by a vims in the subfamily Orthocoronavirinae, or a vims in the family Coronaviridae, or a vims in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a dmg or dmgs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
4.3180854PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
CA 28.10.2021
国際特許分類 (IPC) A61K 31/4706
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
47キノリン;イソキノリン
47064-アミノキノリン;8-アミノキノリン,例.クロロキン,プリマキン
出願番号 3180854 出願人 TOPELIA AUST LIMITED 発明者 BORODY, THOMAS JULIUS
Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma "puffer-like" device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Said drug combinations include various combinations of antivirals, antiparasitics, antibacterials, and adjunct therapeutics, including at least one of Hydroxychloroquine, Chloroquine, Oseltamivir, Lopinavir, Ritonavir, Ribavirin, Favipiravir, Remdesivir, Azithromycin, Ivermectin, Doxycycline, and Opaganib or combinations thereof. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza vims, respiratory syncytial vims, picornavims, parainfluenza vims, adenovims, rhinovims, human metapneumovims, hantavimses, enterovims, a coronavims infection, or a COVID-19 or a 2019-nCoV (SARS-CoV-2) infection, or an infection caused by a vims in the subfamily Orthocoronavirinae, or a vims in the family Coronaviridae, or a vims in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a dmg or dmgs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
5.20230081837PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION
US 16.03.2023
国際特許分類 (IPC) A61K 31/4706
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
47キノリン;イソキノリン
47064-アミノキノリン;8-アミノキノリン,例.クロロキン,プリマキン
出願番号 17798044 出願人 TOPELIA AUSTRALIA PTY LTD 発明者 Thomas Julius BORODY

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.

6.WO/2021/212183PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
WO 28.10.2021
国際特許分類 (IPC) A61K 31/4706
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
47キノリン;イソキノリン
47064-アミノキノリン;8-アミノキノリン,例.クロロキン,プリマキン
出願番号 PCT/AU2021/050369 出願人 TOPELIA AUST LIMITED 発明者 BORODY, Thomas Julius
Provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma "puffer-like" device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Said drug combinations include various combinations of antivirals, antiparasitics, antibacterials, and adjunct therapeutics, including at least one of Hydroxychloroquine, Chloroquine, Oseltamivir, Lopinavir, Ritonavir, Ribavirin, Favipiravir, Remdesivir, Azithromycin, Ivermectin, Doxycycline, and Opaganib or combinations thereof. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza vims, respiratory syncytial vims, picornavims, parainfluenza vims, adenovims, rhinovims, human metapneumovims, hantavimses, enterovims, a coronavims infection, or a COVID-19 or a 2019-nCoV (SARS-CoV-2) infection, or an infection caused by a vims in the subfamily Orthocoronavirinae, or a vims in the family Coronaviridae, or a vims in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a dmg or dmgs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.
7.20230158259PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING MICROBIAL INFECTIONS
US 25.05.2023
国際特許分類 (IPC) A61M 15/08
A生活必需品
61医学または獣医学;衛生学
M人体の中へ,または表面に媒体を導入する装置;人体用の媒体を交換する,または人体から媒体を除去するための装置;眠りまたは無感覚を生起または終らせるための装置
15吸入器
08鼻の中にそう入する吸入装置
出願番号 17921097 出願人 TOPELIA AUST LIMITED 発明者 Thomas Julius BORODY

In alternative embodiments, provided are products of manufacture fabricated or manufactured as medical devices such as an inhaler, an ionizer, an asthma “puffer-like” device, a nebulizer or a nasal spray device, a respirator or a ventilator, a warm or a hot air delivery device, and/or a CPAP (continuous positive air pressure) device (for example, for managing or treating sleep apnea) or equivalent, for delivering one or a combination of medications or drugs, and optionally also warm or hot air, and optionally also ionized air. Products of manufacture are used for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, picornavirus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, products of manufacture as provided herein administer combinations, or cocktails, of a drug or drugs by inhalation, for example, by use of aerosol, mist, liquid or powder formulations for inhalation.

8.11052073Sphingosine kinase 2 inhibitor for treating coronavirus infection
US 06.07.2021
国際特許分類 (IPC) A61K 31/4409
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
44非縮合ピリジン;その水素添加誘導体
44094位のみ置換されたもの,例.イソニアジド,イプロニアジド
出願番号 17195279 出願人 RedHill Biopharma Ltd. 発明者 Dror Ben-Asher

The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

9.WO/2021/191886COMPOSITIONS COMPRISING TERPENES AND TERPENOIDS AND USE THEREOF FOR PREVENTING AND TREATING VIRAL-INDUCED INFECTIONS OF THE RESPIRATORY SYSTEM
WO 30.09.2021
国際特許分類 (IPC) A61K 36/00
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
36藻類,地衣類,菌類もしくは植物またはそれらの派生物からの物質を含有する構造未知の医薬品製剤,例.伝統的生薬
出願番号 PCT/IL2021/050218 出願人 EYBNA TECHNOLOGIES LTD. 発明者 EYAL, Nadav
Provided herein are compositions comprising a plurality of terpenes terpenoids and uses thereof for preventing viral induced severe acute respiratory syndrome (SARS), reducing the risk of infection and treating viral infections.
10.20220031682Sphingosine kinase 2 inhibitor for treating coronavirus infection
US 03.02.2022
国際特許分類 (IPC) A61K 31/4409
A生活必需品
61医学または獣医学;衛生学
K医薬用,歯科用又は化粧用製剤
31有機活性成分を含有する医薬品製剤
33複素環式化合物
395環異種原子として窒素を持つもの,例.グアネチジン,リファマイシン
435環異種原子として1個の窒素のみを有する6員環を持つもの,例.炭素環系と縮合したもの
44非縮合ピリジン;その水素添加誘導体
44094位のみ置換されたもの,例.イソニアジド,イプロニアジド
出願番号 17502932 出願人 RedHill Biopharma Ltd. 発明者 Dror Ben-Asher

The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.